VA-REGULA-FORENSICS
8.6.2021 14:02:08 CEST | Business Wire | Press release
Permission.io, the digital advertising platform that lets online marketers reward users for interacting with ads, announces the integration with the Regula Document Reader SDK to cover the full know-your-customer (KYC) process. The partnership mitigates the risk of fraud and delivers a verified audience to advertisers.
Regula is a global software and hardware manufacturer focused on the verification of identity documents, banknotes, and securities. With 28 years of experience, Regula is a trusted name to experts in both the private and public sectors worldwide. The company has the industry’s largest database of document templates and uses artificial intelligence to automatically determine document type and reveal the visual signs of fraud. Proprietary Face Matching and Liveness Detection technologies make Regula a one-stop solution for identity verification.
Permission.io is a digital advertising platform that enables consumers to earn rewards for interacting with advertisements. The company uses blockchain technology to allow advertisers to reward consumers with ASK, the platform’s native digital currency, for signing up, providing profile and preference data, engaging with video ads, referring friends, and other activities.
“Digital Advertising is ripe for a change,” said Charles Silver, CEO of Permission.io . “Big tech exploits user data, and click fraud is estimated to grow into an $87 billion business in 2021. The major platforms grade their own homework, so to speak, and advertisers are getting the short end of the stick. Too often, the ads they pay to deliver are not even being seen. Permission is bringing the change this industry needs by respecting user data and by delivering to advertisers superior targeting and better ROI on their considerable spend.”
“Financial technology needs the most secure protection from fraud, and we’re happy to share our expertise in document forensics with emerging industry leaders to ensure clear and reliable fraud detection while onboarding and asset management,” said Arif Mamedov, President of Regula Forensics Inc . “Our web and mobile products have been designed to meet the requirements of fintech and to be seamlessly integrable into any scenario and interface.”
Regula Document Reader SDK parses documents and extracts personal data, eliminating manual data input and minimizing mistakes. When it comes to data validation, Regula’s technology cross-checks the data obtained from MRZ, VIZ, and barcodes. The process of user identification is completed with face matching in seconds, while the personal data is secured by the internal Permission network. “We are very excited to add Regula's invaluable expertise to our promise to prevent identity fraud and deliver a delightful user experience,” Silver said.
About Regula Forensics:
Regula is a global software and hardware manufacturer focused on the verification of identity documents, banknotes, and securities. Regula’s software product suite includes ID verification, facematching and liveness technologies for mobile applications and web-based solutions, to build a seamless on-premises digital identity and biometric verification workflow.
135 international borders are equipped with Regula hardware and software products. Regula is an official partner of the UN, Interpol, OSCE, IATA and ICAO. For more information, visit https://mobile.regulaforensics.com .
About Permission.io:
Permission.io is the leading platform for permission advertising for eCommerce. The company has created the ASK digital currency to enable individuals to securely grant permission and monetize their data on Permission.io and 3rd-party e-commerce platforms. Advertisers reward consumers with ASK for interacting with brands and content, building trust, and increasing ROI. To learn more, visit https://permission.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005012/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom